Previously OTP, CD44 and Ki-67 have been identified as prognostic biomarkers in lung carcinoids (lung neuroendocrine tumors or LNETs). We aimed to assess whether risk profiles can be established using these biomarkers on preoperative LNET biopsies . Patients with LNETs (TNM 8 stage I-III, 2003-2021) who underwent curat...
T. V. van Weert, L. Moonen, L. Hillen et al.· Modern Pathology· 0 citations
INTRODUCTION
Lung carcinoids are well-differentiated neuroendocrine tumors (NETs), designated in the current thoracic WHO classification as typical carcinoids (grade 1) and atypical carcinoids (grade 2), whereas rare tumors with carcinoid/NET morphology and >10 mitoses/2mm2 are designated as large cell neuroendocrine c...
N. Rekhtman, Matthew G. Hanna, Paul Hofman et al.· Journal of Thoracic Oncology· 0 citations
In-depth spatial profiling identifies PLA2G2D as a TDLN-centred targetable immune checkpoint for cancer immunotherapy and identifies a specific population of macrophages that express high levels of the enzyme PLA2G2D in tumour-draining lymph nodes that is associated with poor prognosis in patients.
A. van Krimpen, Julie Y. Huang, Mike Eterman et al.· Nature· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.